MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine

MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidineMTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine, Published online: 05 December 2017; doi:10.1038/tpj.2017.48MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine
Source: The Pharmacogenomics Journal - Category: Drugs & Pharmacology Authors: Source Type: research

Related Links:

Authors: Ding WJ, Yang Y, Chen ZX, Wang YY, Dong WL, Cen JN, Qi XF, Jiang F, Chen SN Abstract Previous studies on the pathogenesis of myelodysplastic syndrome (MDS) have identified multiple associated gene mutations, including mutations of tetmethylcytosinedioxygenase 2, isocitrate dehydrogenase [NADP(+)] 1 cytosolic, isocitrate dehydrogenase [NADP(+)] 2 mitochondrial and additional sex combs like 1 transcriptional regulator, all of which may be considered epigenetic regulators. Furthermore, mutations of RAS type GTPase family genes have been identified in 10-15% patients with MDS. The authors' previous study on th...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
The search for the optimal conditioning regimen prior to allogeneic hematopoietic stem cell transplant (HCT) for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) has been ongoing for decades.[1, 2] Early conditioning regimens consisted of high-dose chemotherapy and radiation, now characterized as myeloablative conditioning (MAC), to achieve the aspired outcome of eliminating malignant disease with concomitant restoration of normal hematopoiesis. With experience and improved understanding of the graft-versus-leukemia effect, investigators began to lower the intensity of conditioning regimens.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Aziz Nazha MD of Cleveland Clinic discusses using Personalized Prognoses for Myelodysplastic Syndromes Using Machine Learning at ASH 2018 Author: ASHReport Added: 12/14/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Aziz Nazha MD of Cleveland Clinic discusses the overview of his study of A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplast... Author: ASHReport Added: 12/14/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Authors: Masarova L, Kantarjian H, Ravandi F, Sharma P, Garcia-Manero G, Daver N Abstract In the past few years, our improved understanding of the pathogenesis of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) has led to remarkable advances in the development of novel therapeutic approaches for these diseases. This chapter summarizes the available clinical data with immune-based therapeutic modalities in AML and MDS, focusing on monoclonal antibodies, T cell engager antibodies, chimeric antigen receptor (CAR)-T cells, and checkpoint blockade via blockade of PD-1/PD-L1 or CTLA4. Numerous clinical tr...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Azacitidine may delay or prevent relapse among patients with MRD-positive acute myeloid leukemia or myelodysplastic syndrome.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
New England Journal of Medicine,Volume 379, Issue 24, Page 2379-2380, December 2018.
Source: New England Journal of Medicine - Category: Internal Medicine Source Type: research
Abstract Long noncoding RNAs (lncRNAs), which are regulators of cell differentiation and development. The lncRNA transcriptome in human hematopoietic stem and progenitor cells is not comprehensively defined. We investigated lncRNAs in 979 human bone marrow-derived CD34+ cells by single cell RNA sequencing followed by de novo transcriptome reconstruction. We identified 3,173 lncRNAs in total, among which 2,365 were previously unknown, and we characterized lncRNA stem, differentiation, and maturation signatures. lncRNA expression exhibited high cell-to-cell variation, which was only apparent using a single cell anal...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome &low blast acute myeloid leukemia. Haematologica. 2018 Dec 13;: Authors: Kenealy M, Hertzberg M, Benson W, Taylor K, Cunningham I, Stevenson W, Hiwase D, Eek R, Zantomio D, Jong S, Wall M, Blombery P, Gerber T, Debrincat M, Zannino D, Seymour JF, Australasian Leukaemia and Lymphoma Group Abstract Standard treatment for higher risk myelodysplastic syndromes, chronic myelomonocytic leukemia and low blast acute myeloid leukemia is azacitidine. In single arm studies, adding lenalidomide had been suggested to improve outco...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
Conditions:   Recurrent Acute Myeloid Leukemia;   Recurrent Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia;   Refractory Myelodysplastic Syndrome Interventions:   Drug: Belinostat;   Drug: Pevonedistat Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Drugs & Pharmacology | Genetics | Myelodysplastic Syndrome